Epitomics, Inc.

17 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

Ending by 2030

Sep 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Dec 9 to 16, 2026 · next Dec 9
1 fee due Jan 14, 2027
The maintenance fee for CDR-anchored amplification method (US 9,079,942) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
1 fee due Feb 13, 2027
The maintenance fee for Fusion partner for production of monoclonal rabbit antibodies (US 10,377,814) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
1 fee due Aug 2, 2027
The maintenance fee for Method for identifying lineage-related antibodies (US 9,250,244) comes due Aug 2, 2027. Unpaid by Feb 2, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 10,613,094	Methods for screening and engineering antibodies In force Term ends Sep 25, 2027 · From the USPTO record	In force	Term ends Sep 25, 2027	From the USPTO record
US 10,377,814	Fusion partner for production of monoclonal rabbit antibodies In force Term ends Nov 7, 2027 · From the USPTO record	In force	Term ends Nov 7, 2027	From the USPTO record
US 9,328,333	Fusion partner for production of monoclonal rabbit antibodies In force Term ends Dec 20, 2027 · From the USPTO record	In force	Term ends Dec 20, 2027	From the USPTO record
US 7,803,371	Anti-VEGF antibody In force Term ends Oct 8, 2028 · From the USPTO record	In force	Term ends Oct 8, 2028	From the USPTO record
US 8,088,375	Anti-VEGF antibody In force Term ends Oct 8, 2028 · From the USPTO record	In force	Term ends Oct 8, 2028	From the USPTO record
US 8,293,483	Method for identifying lineage-related antibodies In force Term ends Sep 9, 2030 · From the USPTO record	In force	Term ends Sep 9, 2030	From the USPTO record
US 8,617,830	Method for identifying lineage-related antibodies In force Ends no later than Sep 9, 2030 · From the USPTO record	In force	Ends no later than Sep 9, 2030	From the USPTO record
US 9,052,322	Method for identifying lineage-related antibodies In force Ends no later than Sep 9, 2030 · From the USPTO record	In force	Ends no later than Sep 9, 2030	From the USPTO record
US 9,250,244	Method for identifying lineage-related antibodies In force Ends no later than Sep 9, 2030 · From the USPTO record	In force	Ends no later than Sep 9, 2030	From the USPTO record
US 9,696,314	Method for identifying lineage-related antibodies In force Ends no later than Sep 9, 2030 · From the USPTO record	In force	Ends no later than Sep 9, 2030	From the USPTO record

10 of 17 patents shown.

Pro members see all 17.

Pro members: see all 17 patents

Also on record, not counted in the 17: 1 patent in force now held by others · 2 lapsed for an unpaid fee · 12 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 no status recorded

List them